All In Biotech

BLA 761304 · Argenx Bv

Vyvgart Hytrulo

Efgartigimod Alfa and Hyaluronidase-Qvfc · Injection · Endoglycosidase; Neonatal Fc Receptor Blocker

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jun 20, 2023

Approved uses

6

Original approval plus efficacy supplements

Registered trials

35

9 Phase 3, 9 recruiting

FAERS reports

485

426 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 15, 2026.

VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )

Mechanism: VYVGART HYTRULO is a coformulation of efgartigimod alfa and hyaluronidase. Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. This effect is transient, and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 8, 2026 Supplement 18 · Efficacy · priority review OrphanLetterLabel
  • Oct 17, 2025 Supplement 10 · Efficacy OrphanLabelLetter
  • Apr 10, 2025 Supplement 8 · Efficacy OrphanLabelLetter
  • Aug 8, 2024 Supplement 3 · Efficacy OrphanLetterLabel
  • Jun 21, 2024 Supplement 5 · Efficacy · priority review OrphanLabelLetter
  • Jun 20, 2023 Original approval · priority review OrphanLabelLetterReview
1 products under this application
  • VYVGART HYTRULO · EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC 1008MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Efgartigimod Alfa" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myasthenia gravis68
  • fatigue67
  • asthenia40
  • drug ineffective38
  • fall37
  • muscular weakness37
  • injection site erythema25
  • myasthenia gravis crisis25
  • condition aggravated24
  • headache24
  • injection site pain24
  • therapy change23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20222
202323
2024198
2025132
2026129

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vyvgart Hytrulo (Efgartigimod-Hyaluronidas-Qvfc)

2024 spending

$126M

Beneficiaries

658

2,394 claims

Per beneficiary

$191,644

$2,833.81 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$8,981,322
2024$126,101,725

Part B: Vyvgart Hytrulo (Efgartigimod-Hyaluronidas-Qvfc) · HCPCS J9334

2024 spending

$151M

Beneficiaries

902

8,659 claims

Per beneficiary

$167,216

2024 ASP limit $33.14 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$150,829,226

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: argenx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.